1. Evolution of anti-SARS-CoV-2 spike protein titers after two-dose of COVID-19 vaccination among people living with HIV
- Author
-
Wang-Da Liu, Man Wai Pang, Jann-Tay Wang, Hsin-Yun Sun, Yu-Shan Huang, Kuan-Yin Lin, Un-In Wu, Guei-Chi Li, Wen-Chun Liu, Yi-Ching Su, Pu-Chi He, Chia-Yi Lin, Chih-Yu Yeh, Yu-Chen Cheng, Yi Yao, Yi-Ting Chen, Pei-Ying Wu, Ling-Ya Chen, Yu-Zhen Luo, Hsi-Yen Chang, Wang-Huei Sheng, Szu-Min Hsieh, Sui-Yuan Chang, Chien-Ching Hung, and Shan-Chwen Chang
- Subjects
Antibody ,Humoral immunity ,ChAdOx1 nCoV-19 (AZD1222) vaccine ,mRNA-1273 vaccine ,BNT162b2 vaccine ,Microbiology ,QR1-502 ,Public aspects of medicine ,RA1-1270 - Abstract
Background: A community COVID-19 outbreak caused by the B.1.1.7 SARS-CoV-2 variant occurred in Taiwan in May 2021. High-risk populations such as people living with HIV (PLWH) were recommended to receive two doses of COVID-19 vaccines. While SARS-CoV-2 vaccines have demonstrated promising results in general population, real-world information on the serological responses remains limited among PLWH. Methods: PLWH receiving the first dose of SARS-CoV-2 vaccine from 2020 to 2021 were enrolled. Determinations of anti-SARS-CoV-2 spike IgG titers were performed every one to three months, the third dose of the SARS-CoV-2 vaccine or confirmed SARS-CoV-2 infection. All serum samples were tested for anti-nucleocapsid antibody and those tested positive were excluded from analysis. Results: A total of 1189 PLWH were enrolled: 829 (69.7%) receiving two doses of the AZD1222 vaccine, 232 (19.5%) of the mRNA-1273 vaccine, and 128 (10.8%) of the BNT162b2 vaccine. At all time-points, PLWH receiving two doses of mRNA vaccines had consistently higher antibody levels than those receiving the AZD1222 vaccine (p 141 BAU/mL within 12 weeks, included type 2 diabetes mellitus (DM) (adjusted odds ratio [aOR], 2.24; 95% CI, 1.25–4), a CD4 T cell count 899 BAU/mL within 12 weeks were a CD4 T cell count
- Published
- 2022
- Full Text
- View/download PDF